SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-054514
Filing Date
2021-11-04
Accepted
2021-11-04 16:23:37
Documents
70
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q algs-10q_20210930.htm   iXBRL 10-Q 3216052
2 EX-31.1 algs-ex311_7.htm EX-31.1 18060
3 EX-31.2 algs-ex312_6.htm EX-31.2 18059
4 EX-32.1 algs-ex321_10.htm EX-32.1 8536
5 EX-32.2 algs-ex322_8.htm EX-32.2 8529
  Complete submission text file 0001564590-21-054514.txt   9816856

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA algs-20210930.xsd EX-101.SCH 57157
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE algs-20210930_cal.xml EX-101.CAL 55121
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE algs-20210930_def.xml EX-101.DEF 220091
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20210930_lab.xml EX-101.LAB 482299
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20210930_pre.xml EX-101.PRE 355370
11 EXTRACTED XBRL INSTANCE DOCUMENT algs-10q_20210930_htm.xml XML 1679397
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 211380400
SIC: 2836 Biological Products, (No Diagnostic Substances)